Avalo Therapeutics, Inc. (AVTX)
NASDAQ: AVTX · Real-Time Price · USD
9.08
0.00 (0.00%)
Aug 13, 2025, 4:00 PM - Market open
Avalo Therapeutics Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2015 - 2019 |
|---|---|---|---|---|---|---|---|
Period Ending | Jun '25 Jun 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2015 - 2019 |
| Revenue | 0.44 | 0.44 | 1.92 | 18.05 | 5.4 | 6.7 | Upgrade
|
| Revenue Growth (YoY) | -45.35% | -77.08% | -89.34% | 234.40% | -19.42% | -0.76% | Upgrade
|
| Cost of Revenue | 28.6 | 15.28 | 9.95 | 25.99 | 50.12 | 25.24 | Upgrade
|
| Gross Profit | -28.16 | -14.84 | -8.02 | -7.94 | -44.72 | -18.54 | Upgrade
|
| Selling, General & Admin | 20.31 | 17.24 | 10.3 | 13.91 | 24.66 | 19.76 | Upgrade
|
| Research & Development | 11.68 | 8.8 | 5.12 | 8.05 | 11.21 | 7.26 | Upgrade
|
| Operating Expenses | 31.99 | 26.04 | 15.42 | 22 | 37.41 | 28.76 | Upgrade
|
| Operating Income | -60.16 | -40.87 | -23.44 | -29.94 | -82.13 | -47.29 | Upgrade
|
| Interest Expense | - | - | -3.42 | -4.17 | -2.39 | - | Upgrade
|
| Interest & Investment Income | 4.43 | 3.32 | - | - | - | 0.05 | Upgrade
|
| Other Non Operating Income (Expenses) | 9.64 | 30.18 | -0.76 | -0.02 | -0.02 | 0.41 | Upgrade
|
| EBT Excluding Unusual Items | -46.09 | -7.37 | -27.62 | -34.13 | -84.55 | -46.84 | Upgrade
|
| Merger & Restructuring Charges | - | - | - | -7.5 | - | - | Upgrade
|
| Impairment of Goodwill | - | - | -3.91 | - | - | - | Upgrade
|
| Gain (Loss) on Sale of Investments | - | - | - | - | - | 5.21 | Upgrade
|
| Pretax Income | -46.09 | -35.02 | -31.53 | -41.63 | -84.55 | -67.18 | Upgrade
|
| Income Tax Expense | 0.12 | 0.11 | 0.01 | 0.03 | -0.2 | -2.79 | Upgrade
|
| Earnings From Continuing Operations | -46.22 | -35.13 | -31.54 | -41.66 | -84.35 | -64.38 | Upgrade
|
| Earnings From Discontinued Operations | - | - | - | - | -0.03 | 0.88 | Upgrade
|
| Net Income | -46.22 | -35.13 | -31.54 | -41.66 | -84.38 | -63.5 | Upgrade
|
| Net Income to Common | -46.22 | -35.13 | -31.54 | -41.66 | -84.38 | -63.5 | Upgrade
|
| Shares Outstanding (Basic) | 9 | 4 | 0 | 0 | 0 | 0 | Upgrade
|
| Shares Outstanding (Diluted) | 9 | 7 | 0 | 0 | 0 | 0 | Upgrade
|
| Shares Change (YoY) | 1182.48% | 2599.19% | 608.45% | 8.32% | 41.86% | 28.52% | Upgrade
|
| EPS (Basic) | -4.98 | -7.94 | -113.58 | -1062.65 | -2331.41 | -2489.12 | Upgrade
|
| EPS (Diluted) | -6.01 | -20.91 | -113.58 | -1062.65 | -2331.41 | -2489.12 | Upgrade
|
| Free Cash Flow | -47.42 | -49.06 | -30.84 | -26.85 | -71.01 | -40.6 | Upgrade
|
| Free Cash Flow Per Share | -5.11 | -6.54 | -111.04 | -684.81 | -1961.95 | -1591.55 | Upgrade
|
| Gross Margin | - | - | - | -43.98% | - | -276.70% | Upgrade
|
| Operating Margin | -13640.59% | -9267.80% | -1218.50% | -165.86% | -1521.56% | -705.99% | Upgrade
|
| Profit Margin | -10479.82% | -7965.76% | -1639.50% | -230.78% | -1563.10% | -947.90% | Upgrade
|
| Free Cash Flow Margin | -10752.38% | -11123.81% | -1602.81% | -148.72% | -1315.39% | -606.09% | Upgrade
|
| EBITDA | -59.78 | -40.7 | -23.29 | -29.77 | -80.48 | -45.45 | Upgrade
|
| EBITDA Margin | - | - | - | -164.94% | - | - | Upgrade
|
| D&A For EBITDA | 0.37 | 0.17 | 0.16 | 0.17 | 1.66 | 1.84 | Upgrade
|
| EBIT | -60.16 | -40.87 | -23.44 | -29.94 | -82.13 | -47.29 | Upgrade
|
| EBIT Margin | - | - | - | -165.86% | - | - | Upgrade
|
| Revenue as Reported | 0.44 | 0.44 | 1.92 | 18.05 | 5.4 | 6.7 | Upgrade
|
Updated Aug 7, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.